

12,184 Dead 1,196,190 Injuries: European Database of Adverse Drug Reactions for COVID-19 "Vaccines"

By Brian Shilhavy

Global Research, May 26, 2021

Health Impact News 25 May 2021

Region: Europe

Theme: Science and Medicine

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at @crg globalresearch.

The European database of suspected drug reaction reports is <u>EudraVigilance</u>, which also tracks reports of injuries and deaths following the experimental COVID-19 "vaccines."

Here is what <u>EudraVigilance</u> states about their database:

This website was launched by the <u>European Medicines Agency</u> in 2012 **to provide public access to reports of suspected side effects** (also known as suspected adverse drug reactions). These reports are submitted electronically to <u>EudraVigilance</u> by national medicines regulatory authorities and by pharmaceutical companies that hold marketing authorisations (licences) for the medicines.

EudraVigilance is a system designed for collecting reports of suspected side effects. These reports are used for evaluating the benefits and risks of medicines during their development and monitoring their safety following their authorisation in the European Economic Area (EEA). EudraVigilance has been in use since December 2001.

This website was launched to comply with the <u>EudraVigilance Access Policy</u>, which was developed to improve public health by supporting the monitoring of the safety of medicines and to increase transparency for stakeholders, including the general public.

The <u>Management Board of the European Medicines Agency</u> first approved the EudraVigilance Access Policy in December 2010. A revision was adopted by the Board in December 2015 based on the 2010 pharmacovigilance legislation. The policy aims to provide stakeholders such as national medicines regulatory authorities in the EEA, the European Commission, healthcare professionals, patients and consumers, as well as the pharmaceutical industry and research organisations, with access to reports on suspected side effects.

Transparency is a key guiding principle of the Agency, and is pivotal to building trust and confidence in the regulatory process. By increasing transparency, the Agency is better able to address the growing need among stakeholders, including the general public, for access to information. (Source.)

Their report through May 22, 2021 lists **12,184 deaths and 1,196,190 injuries** following injections of four experimental COVID-19 shots:

- COVID-19 MRNA VACCINE MODERNA (CX-024414)
- COVID-19 MRNA VACCINE PFIZER-BIONTECH
- COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)
- COVID-19 VACCINE JANSSEN (AD26.COV2.S)



EudraVigilance - European database of suspected adverse drug reaction reports

The European Medicines Agency publishes these data so that its stakeholders, including the general public, can access information that European regulatory authorities use to review the safety of a medicine or active substance. **Transparency** is a key guiding principle of the Agency.

COVID-19 Vaccine Adverse Drug Reactions 12,184 DEAD

1,196,190 Injuries Through May 22, 2021

COVID-19 MRNA VACCINE MODERNA (CX-024414)
COVID-19 MRNA VACCINE PFIZER-BIONTECH
COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)
COVID-19 VACCINE JANSSEN (AD26.COV2.S)





From the total of injuries recorded, there are 604,744 **serious** injuries which equals over 50%.

"Seriousness provides information on the suspected undesirable effect; it can be classified as 'serious' if it corresponds to a medical occurrence that results in **death**, is life-threatening, requires inpatient hospitalisation, results in another medically important condition, or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect."

A *Health Impact News* subscriber in Europe ran the reports for each of the four COVID-19 shots we are including here. This subscriber has volunteered to do this, and it is a lot of work to tabulate each reaction with injuries and fatalities, since there is no place on the <u>EudraVigilance</u> system we have found that tabulates all the results.

Since we have started publishing this, others from Europe have also calculated the numbers

Here is the summary data through May 22, 2021.

Total reactions for the experimental mRNA vaccine**Tozinameran** (code **BNT162b2,Comirnaty**) from **BioNTech/ Pfizer: 5,961 deaths** and **452,779** injuries to 22/05/2021

- 13,531 Blood and lymphatic system disorders incl. **59 deaths**
- 9,828 Cardiac disorders incl. 735 deaths
- 71 Congenital, familial and genetic disorders incl. 4 deaths
- 5,468 Ear and labyrinth disorders incl. 3 deaths
- 183 Endocrine disorders
- 6,266 Eye disorders incl. 14 deaths
- 41,214 Gastrointestinal disorders incl. 216 deaths
- 128,031 General disorders and administration site conditions incl. 1,909 deaths
- 327 Hepatobiliary disorders incl. 27 deaths
- 4,802 Immune system disorders incl. 31 deaths
- 13,948 Infections and infestations incl. 648 deaths
- 4,821 Injury, poisoning and procedural complications incl. 81 deaths
- 10,374 Investigations incl. 221 deaths
- 3,354 Metabolism and nutrition disorders incl. 120 deaths
- 65,326 Musculoskeletal and connective tissue disorders incl. 71 deaths
- 250 Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 incl. 15 deaths
- 81,748 Nervous system disorders incl. 616 deaths
- 279 Pregnancy, puerperium and perinatal conditions incl. 7 deaths
- 88 Product issues
- 7,978 Psychiatric disorders incl. 94 deaths
- 1,342 Renal and urinary disorders incl. 93 deaths
- 1,570 Reproductive system and breast disorders **incl. 3 deaths**
- 18,597 Respiratory, thoracic and mediastinal disorders incl. 697 deaths
- 21,101 Skin and subcutaneous tissue disorders incl. 53 deaths
- 663 Social circumstances incl. 9 deaths
- 160 Surgical and medical procedures incl. 10 deaths
- 11,459 Vascular disorders incl. 225 deaths

Total reactions for the experimental mRNA vaccine mRNA-1273(CX-024414) from Moderna: 3,365 deaths and 72,596 injuries to 22/05/2021

- 1,335 Blood and lymphatic system disorders **incl. 22 deaths**
- 2,045 Cardiac disorders incl. 370 deaths
- 12 Congenital, familial and genetic disorders incl. 2 deaths
- 718 Ear and labyrinth disorders
- 37 Endocrine disorders incl. 1 death
- 997 Eye disorders incl. 4 deaths
- 6,305 Gastrointestinal disorders incl. 108 deaths
- 20,774 General disorders and administration site conditions incl. 1,480
 deaths
- 129 Hepatobiliary disorders incl. 8 deaths

- 691 Immune system disorders incl. 4 deaths
- 2,392 Infections and infestations incl. 183 deaths
- 1,292 Injury, poisoning and procedural complications incl. 63 deaths
- 1,743 Investigations incl. 77 deaths
- 816 Metabolism and nutrition disorders incl. 64 deaths
- 9,149 Musculoskeletal and connective tissue disorders incl. 62 deaths
- 77 Neoplasms benign, malignant and unspecified (incl cysts and polyps)

incl. 11 deaths

- 12,314 Nervous system disorders incl. 339 deaths
- 83 Pregnancy, puerperium and perinatal conditions
- 11 Product issues
- 1,375 Psychiatric disorders incl. 51 deaths
- 468 Renal and urinary disorders incl. 40 deaths
- 175 Reproductive system and breast disorders incl. 1 death
- 3,513 Respiratory, thoracic and mediastinal disorders incl. 306 deaths
- 3,726 Skin and subcutaneous tissue disorders incl. 23 deaths
- 259 Social circumstances incl. 9 deaths
- 235 Surgical and medical procedures incl. 26 deaths
- 1,925 Vascular disorders

Total reactions for the experimental vaccine AZD1222/VAXZEVRIA (CHADOX1 NCOV-19) from Oxford/ AstraZeneca: 2,489 deaths and 655,534 injuries to 22/05/2021

- 7,200 Blood and lymphatic system disorders incl. 100 deaths
- 9,748 Cardiac disorders incl. 311 deaths
- 103 Congenital, familial and genetic disorders incl. 2 deaths
- 6,740 Ear and labyrinth disorders
- 217 Endocrine disorders incl. 2 deaths
- 10,591 Eye disorders incl. 8 deaths
- 69,826 Gastrointestinal disorders incl. 116 deaths
- 178,037 General disorders and administration site conditions incl. 685 deaths
- 396 Hepatobiliary disorders incl. 20 deaths
- 2,409 Immune system disorders incl. 9 deaths
- 13,832 Infections and infestations incl. 163 deaths
- 5,870 Injury, poisoning and procedural complications incl. 46 deaths
- 13,474 Investigations incl. 50 deaths
- 8.405 Metabolism and nutrition disorders **incl. 35 deaths**
- 104,075 Musculoskeletal and connective tissue disorders incl. 25 deaths
- 222 Neoplasms benign, malignant and unspecified (incl cysts and polyps)

incl. 6 deaths

- 141,437 Nervous system disorders incl. 388 deaths
- 156 Pregnancy, puerperium and perinatal conditions incl. 3 deaths
- 76 Product issues
- 12,272 Psychiatric disorders incl. 21 deaths
- 2,264 Renal and urinary disorders incl. 20 deaths
- **3,327** Reproductive system and breast disorders
- 21,237 Respiratory, thoracic and mediastinal disorders incl. 278 deaths
- 29,750 Skin and subcutaneous tissue disorders incl. 14 deaths
- 582 Social circumstances incl. 4 deaths

- 498 Surgical and medical procedures incl. 15 deaths
- 12.790 Vascular disorders incl. 168 deaths

Total reactions for the experimental COVID-19 vaccine JANSSEN (AD26.COV2.S) from <u>Johnson & Johnson</u>: 369 deaths and 15,281 injuries to 22/05/2021

- 145 Blood and lymphatic system disorders incl. 10 deaths
- 264 Cardiac disorders incl. 34 deaths
- 8 Congenital, familial and genetic disorders
- 77 Ear and labyrinth disorders
- 5 Endocrine disorders incl. 1 death
- 191 Eye disorders incl. 2 deaths
- 1,302 Gastrointestinal disorders incl. 11 deaths
- 3,619 General disorders and administration site conditions incl. 97 deaths
- 38 Hepatobiliary disorders incl. 2 deaths
- 51 Immune system disorders
- 245 Infections and infestations incl. 8 deaths
- 209 Injury, poisoning and procedural complications incl. 6 deaths
- 1,134 Investigations incl. 23 deaths
- 104 Metabolism and nutrition disorders incl. 10 deaths
- 2,368 Musculoskeletal and connective tissue disorders incl. 12 deaths
- 12 Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- 3,051 Nervous system disorders incl. 48 death
- 7 Pregnancy, puerperium and perinatal conditions
- 8 Product issues
- 181 Psychiatric disorders incl. 3 deaths
- 69 Renal and urinary disorders incl. 4 deaths
- 62 Reproductive system and breast disorders
- 637 Respiratory, thoracic and mediastinal disorders incl. 29 deaths
- 324 Skin and subcutaneous tissue disorders incl. 1 death
- 39 Social circumstances incl. 2 deaths
- 214 Surgical and medical procedures incl. 20 deaths
- 917 Vascular disorders incl. 46 deaths

Last Update: May 22 2021	Reported Cases	Fatalities	All Multiple Symptoms	Serious injuries	
Astrazeneca	237 648	2 489	655 534	372 019	56,75%
Pfizer-BioNTech	191 215	5 961	452 779	186 308	41,15%
Moderna	29 616	3 365	72 596	38 704	53,31%
Jannsen	4 997	369	15 281	7 713	50,47%
Total:	463 476	12 184	1 196 190	604 744	50,56%

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Notes

[1] These totals are estimates based on reports submitted to EudraVigilance. Totals may be much

higher based on percentage of adverse reactions that are reported. Some of these reports may also be reported to the individual country's adverse reaction databases, such as the U.S. VAERS database, and the UK Yellow Card system. The fatalities are grouped by symptoms, and some fatalities may have resulted from multiple symptoms.

Featured image is from Health Impact News

The original source of this article is <u>Health Impact News</u> Copyright © <u>Brian Shilhavy</u>, <u>Health Impact News</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: **Brian Shilhavy**

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca